RenovoRx Inc
renovorx.comRenovoRx Inc (NASDAQ: RNXT) is a clinical-stage medical device and drug delivery company developing localized cancer treatment technology. The company's primary asset is RenovoCath, a dual-balloon catheter delivery system designed to isolate arterial segments and deliver therapeutics directly to tumor sites, with a focus on pancreatic cancer. RenovoRx has not generated meaningful product revenue as of its FY2025 10-K filing and funds operations through equity financing. Net cash used in operating activities was $11.0 million for the year ended December 31, 2025, driven by a net loss of $11.2 million. The company is commercializing RenovoCath as a standalone device while simultaneously pursuing clinical development of combination drug-device product candidates. RenovoRx holds multiple issued and pending utility patents covering its dual-balloon catheter apparatus and Trans-Arterial Micro-Perfusion (TAMP) methods, with key U.S. patents expiring between 2030 and 2038. Headquartered in Silicon Valley, California, the company has not declared or paid any cash dividends since inception as of March 2026.
Products & Services
RenovoCath: a dual-balloon catheter delivery system for localized arterial drug delivery. Trans-Arterial Micro-Perfusion (TAMP): a patented method for delivering therapeutics to tumors via arterial isolation. Pipeline includes product candidates targeting pancreatic cancer and bile duct treatment.
Revenue Model
RenovoRx has no established commercial revenue stream as of FY2025. Operations are funded through equity financing. The company is pursuing commercialization of RenovoCath as a standalone medical device while clinical development of drug-device combination candidates continues.
Customers & Markets
End market is oncology, with a stated focus on pancreatic cancer treatment. Direct customers would be hospitals and interventional radiology or oncology centers, though no customer concentration data is disclosed in the filing excerpts.
Geographic Exposure
Headquartered in Silicon Valley, California. Patents filed and issued in the U.S., EU member states (BE, CH, DE, ES, FR, GB, IE, IT, NL), India, and China, indicating international IP strategy, though no commercial geographic revenue breakdown is disclosed.
Financial Snapshot
Loading...
